Advertisement

Topics

Prostate Cancer Drug Receives Positive Top-Line Results

10:25 EDT 14 Sep 2017 | PharmPro

Pfizer and Astellas announce positive top-line results from Phase 3 PROSPER trial of Xtandi (enzalutamide) in patients with non-metastatic castration-resistant prostate cancer.
Contributed Author: 
Astellas Pharma Inc.

Original Article: Prostate Cancer Drug Receives Positive Top-Line Results

NEXT ARTICLE

More From BioPortfolio on "Prostate Cancer Drug Receives Positive Top-Line Results"

Quick Search
Advertisement
 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...